Find disease awareness content and relevant supporting materials
Indacaterol/glycopyrronium: a dual bronchodilator for COPD.
Indacaterol/glycopyrronium (IND/GLY) 110/50mcg was the first once-daily, long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combination (FDC) approved in Europe for the treatment of chronic obstructive pulmonary disease (COPD).
The asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): opportunities and challenges.
Purpose of review: Some individuals share characteristics of asthma and chronic obstructive pulmonary disease (COPD). The asthma-COPD overlap syndrome (ACOS) has been defined as symptoms of increased variability of airflow in association with an incompletely reversible airflow obstruction.
Diagnosis and Outpatient Management of Chronic Obstructive Pulmonary Disease: A Review.
Importance: There are 30 million adults (12%) in the United States who have chronic obstructive pulmonary disease (COPD). Chronic obstructive pulmonary disease accounts for 3.2% of all physician office visits annually and is the fourth leading cause of death (126 000 deaths per year).
No impact of exacerbation frequency and severity on the physical activity decline in COPD: a long-term observation.
Introduction: COPD exacerbations are associated with a concomitant profound reduction in daily physical activity (PA). Thereby, exacerbation frequency and severity may have an amplifying effect.
Chronic obstructive pulmonary disease is not a risk factor for polyneuropathy: A prospective controlled study.
Polyneuropathy has been observed in patients with chronic obstructive pulmonary disease (COPD). If polyneuropathy occurs as a complication or extrapulmonary manifestation of COPD, one would expect an increased prevalence among patients with a cryptogenic axonal polyneuropathy.
Revefenacin for the treatment of chronic obstructive pulmonary disease.
Areas covered: In this paper, the chemical properties, mechanism of action, pharmacokinetics, clinical efficacy and safety of Revefenacin was introduced, and the evolution of muscarinic antagonists is also briefly described.